Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
National Institutes of Health · Opportunity PAR-25-175
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Award history — this exact opportunity
NIH RePORTER lists 1 funded award under PAR-25-175 across 1 organization.
Total award obligations, not per-year amounts.
Recent awardees include: MAYO CLINIC ROCHESTER.
Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.
Portfolio context — this listing covers more than this opportunity
This opportunity is funded under Assistance Listing 93.393 (“Cancer Cause and Prevention Research”), a broad federal program that made about 318 new awards per year over the last five fiscal years (median award $1.1M). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.
Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. NIH publishes success rates by institute and activity code — source.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) | National Institutes of Health | September 25, 2026 16d left | — | Nonprofits |
| National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) | National Institutes of Health | September 28, 2026 19d left | $400k | Nonprofits |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) | National Institutes of Health | October 14, 2026 35d left | — | Nonprofits |
| NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) | National Institutes of Health | October 14, 2026 35d left | — | Nonprofits |